Navigation Links
Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
Date:11/14/2011

pleted an FDA-approved Phase Ia safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depression, and expects to receive Phase Ib trial approval in the fall.  Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For more information, please go to www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2010 and the  quarterly report on Form 10-Q for the period ended September 30, 2011.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neuralstem Reports Second Quarter Financial Results and Highlights
2. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
3. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
4. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
6. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
7. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
8. Neuralstem Completes $5.25 Million Financing
9. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
10. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
11. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Senomyx , Inc. ... using proprietary taste science technologies to discover, develop, ... beverage, and ingredient supply industries, today reported financial ... ended the second quarter with $33.6 million in ... "During the past quarter Senomyx achieved another important ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 ... today the integration of Omicsoft’s Array Suite with ... platforms will be able to send data in tranSMART ... works with all versions of tranSMART including the new ... art statistics, visualization and storage for the analysis of ...
(Date:7/31/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues, today announced today ... be released on Thursday, August 7, 2014, and that ... webcast at 4:30 p.m. ET that afternoon. Management will ...
(Date:7/31/2014)... Scottsdale, AZ (PRWEB) July 31, 2014 ... the availability of its online sales training course – ... salespeople improve their sales performance. , Drawn from proven ... Fortune 500 companies, Mastering the Complex Sale online sales ... as to anyone who has face-to-face contact with customers, ...
Breaking Biology Technology:SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3
... MBF Healthcare,Acquisition Corp. (Amex: MBH ), a ... it and Critical Home Solutions,Holdings, Inc., a privately-owned, ... infusion services, are scheduled to present,on Wednesday, February ... in New York, NY. On February 7, 2008, ...
... CITY, Calif., Feb. 12 /PRNewswire-FirstCall/ . Maxygen, Inc.,(Nasdaq: ... the development of,improved protein drugs, today reported financial ... 31, 2007. At December 31, 2007, cash, cash,equivalents ... million at December 31, 2006., "After a ...
... 12 WaferGen Biosystems,Inc. (OTC Bulletin Board: WGBS), ... biology and stem cell research systems,today announced that ... deliver a corporate presentation at the Roth Capital ... will be held,February 18-21, 2008, at the Ritz-Carlton ...
Cached Biology Technology:MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 2008 UBS Healthcare Services Conference 2MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 2008 UBS Healthcare Services Conference 3Maxygen Reports Fourth Quarter and Year End 2007 Financial Results 2Maxygen Reports Fourth Quarter and Year End 2007 Financial Results 3Maxygen Reports Fourth Quarter and Year End 2007 Financial Results 4Maxygen Reports Fourth Quarter and Year End 2007 Financial Results 5Maxygen Reports Fourth Quarter and Year End 2007 Financial Results 6WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference 2
(Date:7/31/2014)... Alexandre Edmond Becquerel first discovered the photovoltaic effect in ... the power of sunlight for its own purposes. In ... issue of the FASEB Journal , ... the power of sunlight by focusing on a naturally ... throughout evolution. This conservationor persistence over time and across ...
(Date:7/31/2014)... In the same week that the U.S. surgeon general ... cancer, researchers at Montana State University published a paper ... code in every cell responds when exposed to ... of DNA damage by the UV rays found in ... and some degenerative eye diseases. , "Our paper ...
(Date:7/31/2014)... Dr. Oren Tessler, Assistant Professor of Clinical Surgery at ... is part of a team of plastic and reconstructive ... method to screen and select patients for a specific ... patients who underwent this surgery to decompress the nerves ... bonus cosmetic eyelid surgery. The study, which confirms the ...
Breaking Biology News(10 mins):Scientists shine bright new light on how living things capture energy from the sun 2New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2
... California, Berkeley, virologist and an assistant professor in the Department ... Keck Foundation grant, an award given to innovative young scientists ... totals up to $1 million over five years, will go ... as a tool to study the inner workings of human ...
... to a cause of death but now a study of ... cause of major depression and suicide. The international research ... Institute at The University of Western Ontario and Dr. Hymie ... the first to show that proteins that modify DNA directly ...
... Researchers at the University of California, San Francisco, have identified ... killing parrots and exotic birds for more than 30 years. ... PhD, and Don Ganem, MD, also has developed a diagnostic ... PDD, which will enable veterinarians worldwide to control the spread ...
Cached Biology News:UC Berkeley virologist named Keck Distinguished Young Scholar 2Study identifies changes to DNA in major depression and suicide 2UCSF researchers identify virus behind mysterious parrot disease 2